Sai Life Sciences Limited — Updates, 08-08-2025: Press Release

Sai Life Sciences reported strong Q1FY26 results with Revenue at ₹496 Cr, up 77% YoY, driven by robust CDMO growth (113%). EBITDA surged 303% to ₹125 Cr, expanding margins to 25%. Net Profit hit ₹60 Cr. The company invested ₹134 Cr in capex, expanding manufacturing capacity to ~700 KL and initiating an additional 200 KL expansion. New R&D facilities, including a Peptide Research Center and Biology facility, were inaugurated, and a new Process R&D Block commenced, bolstering capabilities in complex modalities and discovery. 253 new staff onboarded.